USD 0.23
(-5.78%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.7 Million USD | 41.39% |
2022 | 1.2 Million USD | 8.83% |
2021 | 1.11 Million USD | -31.65% |
2020 | 1.62 Million USD | -39.72% |
2019 | 2.69 Million USD | -24.36% |
2018 | 3.56 Million USD | -80.48% |
2017 | 18.24 Million USD | 36.04% |
2016 | 13.41 Million USD | 47.31% |
2015 | 9.1 Million USD | -18.58% |
2014 | 11.18 Million USD | -19.1% |
2013 | 13.81 Million USD | 948.79% |
2012 | 1.31 Million USD | 8.51% |
2011 | 1.21 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 3.89 Million USD | 125.26% |
2024 Q1 | 1.73 Million USD | 1.29% |
2023 Q4 | 1.7 Million USD | 4.27% |
2023 Q2 | 1.23 Million USD | -0.08% |
2023 FY | 1.7 Million USD | 41.39% |
2023 Q3 | 1.63 Million USD | 32.2% |
2023 Q1 | 1.24 Million USD | 2.65% |
2022 Q2 | 1.12 Million USD | -0.09% |
2022 Q3 | 1.15 Million USD | 2.57% |
2022 Q4 | 1.2 Million USD | 4.5% |
2022 FY | 1.2 Million USD | 8.83% |
2022 Q1 | 1.12 Million USD | 1.62% |
2021 Q3 | 1.13 Million USD | -14.31% |
2021 Q4 | 1.11 Million USD | -1.94% |
2021 Q1 | 1.47 Million USD | -8.93% |
2021 FY | 1.11 Million USD | -31.65% |
2021 Q2 | 1.32 Million USD | -10.68% |
2020 Q4 | 1.62 Million USD | 6.41% |
2020 Q1 | 2.38 Million USD | -11.44% |
2020 FY | 1.62 Million USD | -39.72% |
2020 Q2 | 1.79 Million USD | -24.93% |
2020 Q3 | 1.52 Million USD | -14.79% |
2019 FY | 2.69 Million USD | -24.36% |
2019 Q1 | 3.52 Million USD | -1.01% |
2019 Q3 | 2.83 Million USD | -6.69% |
2019 Q4 | 2.69 Million USD | -5.02% |
2019 Q2 | 3.03 Million USD | -13.78% |
2018 FY | 3.56 Million USD | -80.48% |
2018 Q4 | 3.56 Million USD | -80.7% |
2018 Q3 | 18.45 Million USD | -0.18% |
2018 Q2 | 18.48 Million USD | 1.62% |
2018 Q1 | 18.19 Million USD | -0.29% |
2017 Q1 | 16.06 Million USD | 19.79% |
2017 Q2 | 16.75 Million USD | 4.29% |
2017 FY | 18.24 Million USD | 36.04% |
2017 Q3 | 17.49 Million USD | 4.41% |
2017 Q4 | 18.24 Million USD | 4.3% |
2016 Q3 | 11.96 Million USD | 4.06% |
2016 FY | 13.41 Million USD | 47.31% |
2016 Q4 | 13.41 Million USD | 12.06% |
2016 Q2 | 11.49 Million USD | 17.82% |
2016 Q1 | 9.76 Million USD | 7.22% |
2015 Q4 | 9.1 Million USD | 4.98% |
2015 FY | 9.1 Million USD | -18.58% |
2015 Q3 | 8.67 Million USD | -0.23% |
2015 Q2 | 8.69 Million USD | -8.09% |
2015 Q1 | 9.45 Million USD | -15.42% |
2014 Q4 | 11.18 Million USD | 13.33% |
2014 Q1 | 13.85 Million USD | 0.25% |
2014 Q2 | 7.73 Million USD | -44.18% |
2014 FY | 11.18 Million USD | -19.1% |
2014 Q3 | 9.86 Million USD | 27.56% |
2013 Q3 | 7.65 Million USD | -0.99% |
2013 Q2 | 7.73 Million USD | -1.74% |
2013 Q4 | 13.81 Million USD | 80.56% |
2013 Q1 | 7.86 Million USD | 497.06% |
2013 FY | 13.81 Million USD | 948.79% |
2012 Q3 | 1.24 Million USD | 0.96% |
2012 Q1 | 1.27 Million USD | 4.8% |
2012 Q2 | 1.23 Million USD | -3.32% |
2012 FY | 1.31 Million USD | 8.51% |
2012 Q4 | 1.31 Million USD | 6.08% |
2011 Q4 | 1.21 Million USD | 0.1% |
2011 FY | 1.21 Million USD | 0.0% |
2011 Q3 | 1.21 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Akoya Biosciences, Inc. | 126.59 Million USD | 98.651% |
AngioDynamics, Inc. | 112.08 Million USD | 98.476% |
AtriCure, Inc. | 147.76 Million USD | 98.844% |
Avinger, Inc. | 19.97 Million USD | 91.448% |
Azenta, Inc. | 351.22 Million USD | 99.514% |
BioLife Solutions, Inc. | 75.05 Million USD | 97.724% |
The Cooper Companies, Inc. | 4.1 Billion USD | 99.958% |
Daxor Corporation | 858.75 Thousand USD | -98.892% |
Ekso Bionics Holdings, Inc. | 16.31 Million USD | 89.529% |
Femasys Inc. | 9.4 Million USD | 81.836% |
Harvard Bioscience, Inc. | 64.29 Million USD | 97.343% |
Hologic, Inc. | 4.02 Billion USD | 99.958% |
ICU Medical, Inc. | 2.25 Billion USD | 99.924% |
Intuitive Surgical, Inc. | 2.04 Billion USD | 99.916% |
KORU Medical Systems, Inc. | 8.1 Million USD | 78.932% |
LeMaitre Vascular, Inc. | 48.87 Million USD | 96.506% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -158.813% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -158.813% |
Masimo Corporation | 1.67 Billion USD | 99.898% |
Microbot Medical Inc. | 3.82 Million USD | 55.358% |
Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 93.189% |
Merit Medical Systems, Inc. | 1.12 Billion USD | 99.848% |
Nephros, Inc. | 3.5 Million USD | 51.242% |
NovoCure Limited | 783.63 Million USD | 99.782% |
NEXGEL, Inc. | 4.78 Million USD | 64.335% |
NEXGEL, Inc. | 4.78 Million USD | 64.335% |
Singular Genomics Systems, Inc. | 86.46 Million USD | 98.025% |
OraSure Technologies, Inc. | 52.17 Million USD | 96.726% |
Pro-Dex, Inc. | 23.34 Million USD | 92.683% |
Pulse Biosciences, Inc. | 16.44 Million USD | 89.613% |
Predictive Oncology Inc. | 6.14 Million USD | 72.207% |
Precision Optics Corporation, Inc. | 6.84 Million USD | 75.047% |
QuidelOrtho Corporation | 3.55 Billion USD | 99.952% |
Repligen Corporation | 853.2 Million USD | 99.8% |
Sanara MedTech Inc. | 29.28 Million USD | 94.167% |
STAAR Surgical Company | 102.73 Million USD | 98.338% |
Sharps Technology, Inc. | 3.85 Million USD | 55.694% |
Utah Medical Products, Inc. | 7.14 Million USD | 76.095% |
DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.958% |
Jin Medical International Ltd. | 8.92 Million USD | 80.861% |